The FDA has approved broader use of bempedoic acid and its combination with ezetimibe for preventing heart attacks and cardiovascular procedures.

The new indications cover both primary- and secondary-prevention patients, significantly extending the eligible patient population.

Eligibility for these medications now exceeds 70 million patients and no longer requires concurrent statin therapy.

The expansion was informed by the CLEAR Outcomes trial, which demonstrated the efficacy of bempedoic acid in lowering LDL-C and reducing cardiovascular risk.

Updated prescribing information for bempedoic acid and the combination therapy is now available online.